Resources
Featured Articles
INDUSTRY PUBLICATION
Clinical Trial Supply and Logistics Supplement: Quality assurance and regulatory compliance, and ancillary supply chain management
WHITE PAPER
The Drivers of Success in Ancillary Supply Chain Management
ARTICLE
Ancillare Answers: How Do You Ensure a Flexible Supply Chain in Times of Global Turmoil?
All Insights & Results
Featured Resources
White Papers
Articles
Industry Publications
Ebooks
Clinical Trial Supply and Logistics Supplement: Quality assurance and regulatory compliance, and ancillary supply chain management
The clinical trial ancillary supply chain (CTASC) is extremely diverse and complex. Although the CTASC has evolved dramatically during most recent years, one element holds true – CTASC performance has the potential to significantly disrupt trial timelines and patient outcomes.
To Research Faster, You Need an Ancillary Partner Who Reaches Further
Sponsors could achieve over 30% in cost savings by optimizing how they manage their trial’s ancillaries. Ancillary supply and equipment programs are a strategic investment, not an expense.
Ancillare Answers: How Do You Ensure a Flexible Supply Chain in Times of Global Turmoil?
As major world events continue to unfold, every organization is contending with supply chain disruptions. Challenges with Clinical Trial Ancillary Supply Chain (CTASC™) are not going away. Ancillare remains at the forefront of supply chain innovation, and stays committed to helping Sponsors overcome setbacks and achieve their clinical trial milestones.
Know + Know How: Reengineering Consultative Partnerships in CTASC™ Management
Today’s clinical research environment requires cooperation and insight across countless organizations, teams, and specialists. More and more, Sponsors are turning to trusted third parties with high levels of expertise to make their trials run effectively.
Clinical Trials Insights 2021 – Stay Ahead of the Supply Chain
A lack of correct ancillary supplies can be the difference between a clinical trial starting on time or having to delay at significant cost to the sponsor. The Covid-19 pandemic exacerbated what would already be a difficult task of sourcing and purchasing trial equipment. Ancillare CEO Joanne Santomauro explains how the situation developed and how her company stayed ahead of the curve and minimised the impact of shortages in the supply chain.
Cervical Cancer & CTASC™: Improving the Future of Women’s Health Research
January is Cervical Health Awareness Month. Dr. John Fitzgerald, Medical Director and Subject Matter Expert at Ancillare, shares insights from decades in the women’s health field to raise awareness of cervical cancer and other conditions, discuss the importance of preventive services, and highlight the potential of Decentralized Trials to advance necessary research.
PharmaVOICE Supply Chain SHOWCASE: The Cost of Overlooking Ancillary Supplies in Protocol Development
What will it take to overcome grand-scale supply chain challenges, avoid massive business ramifications, and produce the best possible outcomes for patients worldwide?
Prepared vs. Proactive: Is Your Clinical Trial Ancillary Supply Chain™ Supporting Trial Success?
As the effects of the pandemic reverberate through global supply chains, Sponsors still face many hurdles in sourcing and managing ancillary supplies for clinical trials. Interruptions and delays that once felt like temporary inconveniences are now long-term realities across the entire industry, and there is no choice except to adapt.
DCAT® Women Leaders in Pharma Interview Series: Dr. Joanne Santomauro
Dr. Joanne Santomauro, Chief Executive Officer and Founder of Ancillare, LP, created the Clinical Trial Ancillary Supply Chain (CTASC™) Management industry in 2006. Joanne’s 35 years of supply chain management expertise led the company to launch its market-leading model. Her leadership has resulted in Ancillare’s explosive growth throughout the world.
Ancillare’s Impact: Our Drive to Reach Further (And Closer)
Our work to make clinical trials run more smoothly helps our partners create hope for patients every day, all over the world.
Risk Management in Clinical Trials: How the CTASC™ Approach Strengthens Clinical Supply Chains
Minimizing interruptions in your Clinical Trial Ancillary Supply Chain lowers risk of delay in your trial timeline — potentially saving millions in overall trial costs.
Ensuring uninterrupted clinical supplies during a pandemic
Ancillare’s CEO, Dr. Joanne Santomauro, discusses how the organization overcame supply chain challenges in the height of the COVID-19 pandemic to source ancillary supplies for clinical trials.
Dry Eye Syndrome
Dry eye syndrome is a common condition with many ongoing studies around the globe. Read the overview by Ancillare’s Medical Director, including ancillary considerations for clinical supply chains.
Your Trials Deserve More Than an Ancillary Supply Vendor
This Clinical Trials Day, we are highlighting the individual areas of expertise that allows us to serve as much more than a supplier.
Armed Against ARMD – Insights for Providers, Patients, and Clinical Trial Sponsors
February is Age-Related Macular Degeneration (ARMD) and Low Vision Awareness month. Dr. Georgia Crozier, Medical Director and Subject Matter Expert at Ancillare, shares her decades of experience to raise public awareness on this common condition — and highlights the importance of a well-planned Clinical Trial Ancillary Supply Chain (CTASC™) in conducting research for potential treatments.
PharmaVOICE SHOWCASE: Supply Chain Management: The Supply Chain: Risks and Opportunities with Executive Viewpoints from Ancillare’s CEO
COVID-19 caused shockwaves throughout the global supply chain of every industry. For the pharmaceutical industry, the pandemic highlighted the fragility of the supply chain and the importance of being able to adjust to demand in a changed environment.
PharmaVOICE Technology Solutions: Disrupting Innovations with Digital Solutions with Executive Viewpoints from Ancillare’s CIO
Healthcare is undergoing a massive transformation with increased emphasis on digital technologies in all areas. According to Deloitte research, biopharma companies recognize that digital transformation will aid product and service innovation, greater customer engagement, and improvements across R&D, commercial, and the supply chain.
The Future of Clinical Trials is Now
The COVID-19 pandemic has created numerous challenges for Sponsors worldwide, forcing clinical trials to adapt to changing conditions and innovate for the future simultaneously. Ancillare CEO Dr. Joanne Santomauro was interviewed on how proper supply plans are...
The Drivers of Success in Ancillary Supply Chain Management
With an emerging Clinical Trial Ancillary Supply Chain™, and little research into effective management models, it has never been more urgent for management systems to step up to an increasingly complex trial landscape. Today’s pharmaceutical landscape relies...
Tackling Ancillary Supply Challenges with Innovative Solutions
When a pharmaceutical client came to Joanne Santomauro nearly 15 years ago with a request to help with a complex and expensive ancillary supply challenge, she didn’t hesitate. She launched Ancillare and began the journey to create and revolutionize ancillary supply...
The Evolution from Commodity Procurement to a Systemic Supply Chain Model
According to the U.S. National Institutes of Health, nearly 240,000 clinical trials were registered as of February 2017, comprising all 50 U.S. states and 195 countries. More strikingly, over half of these studies included global (i.e., non-U.S.) sites. Global...
Ancillare Answers: How Do You Ensure a Flexible Supply Chain in Times of Global Turmoil?
As major world events continue to unfold, every organization is contending with supply chain disruptions. Challenges with Clinical Trial Ancillary Supply Chain (CTASC™) are not going away. Ancillare remains at the forefront of supply chain innovation, and stays committed to helping Sponsors overcome setbacks and achieve their clinical trial milestones.
Clinical Trials Insights 2021 – Stay Ahead of the Supply Chain
A lack of correct ancillary supplies can be the difference between a clinical trial starting on time or having to delay at significant cost to the sponsor. The Covid-19 pandemic exacerbated what would already be a difficult task of sourcing and purchasing trial equipment. Ancillare CEO Joanne Santomauro explains how the situation developed and how her company stayed ahead of the curve and minimised the impact of shortages in the supply chain.
The Drivers of Success in Ancillary Supply Chain Management
With an emerging Clinical Trial Ancillary Supply Chain™, and little research into effective management models, it has never been more urgent for management systems to step up to an increasingly complex trial landscape. Today’s pharmaceutical landscape relies...
The Drivers of Success in Ancillary Supply Chain Management
With an emerging Clinical Trial Ancillary Supply Chain™, and little research into effective management models, it has never been more urgent for management systems to step up to an increasingly complex trial landscape. Today’s pharmaceutical landscape relies...
The Evolution from Commodity Procurement to a Systemic Supply Chain Model
According to the U.S. National Institutes of Health, nearly 240,000 clinical trials were registered as of February 2017, comprising all 50 U.S. states and 195 countries. More strikingly, over half of these studies included global (i.e., non-U.S.) sites. Global...
Clinical Trial Supply and Logistics Supplement: Quality assurance and regulatory compliance, and ancillary supply chain management
The clinical trial ancillary supply chain (CTASC) is extremely diverse and complex. Although the CTASC has evolved dramatically during most recent years, one element holds true – CTASC performance has the potential to significantly disrupt trial timelines and patient outcomes.
To Research Faster, You Need an Ancillary Partner Who Reaches Further
Sponsors could achieve over 30% in cost savings by optimizing how they manage their trial’s ancillaries. Ancillary supply and equipment programs are a strategic investment, not an expense.
Ancillare Answers: How Do You Ensure a Flexible Supply Chain in Times of Global Turmoil?
As major world events continue to unfold, every organization is contending with supply chain disruptions. Challenges with Clinical Trial Ancillary Supply Chain (CTASC™) are not going away. Ancillare remains at the forefront of supply chain innovation, and stays committed to helping Sponsors overcome setbacks and achieve their clinical trial milestones.
Know + Know How: Reengineering Consultative Partnerships in CTASC™ Management
Today’s clinical research environment requires cooperation and insight across countless organizations, teams, and specialists. More and more, Sponsors are turning to trusted third parties with high levels of expertise to make their trials run effectively.
Clinical Trials Insights 2021 – Stay Ahead of the Supply Chain
A lack of correct ancillary supplies can be the difference between a clinical trial starting on time or having to delay at significant cost to the sponsor. The Covid-19 pandemic exacerbated what would already be a difficult task of sourcing and purchasing trial equipment. Ancillare CEO Joanne Santomauro explains how the situation developed and how her company stayed ahead of the curve and minimised the impact of shortages in the supply chain.
Cervical Cancer & CTASC™: Improving the Future of Women’s Health Research
January is Cervical Health Awareness Month. Dr. John Fitzgerald, Medical Director and Subject Matter Expert at Ancillare, shares insights from decades in the women’s health field to raise awareness of cervical cancer and other conditions, discuss the importance of preventive services, and highlight the potential of Decentralized Trials to advance necessary research.
PharmaVOICE Supply Chain SHOWCASE: The Cost of Overlooking Ancillary Supplies in Protocol Development
What will it take to overcome grand-scale supply chain challenges, avoid massive business ramifications, and produce the best possible outcomes for patients worldwide?
Prepared vs. Proactive: Is Your Clinical Trial Ancillary Supply Chain™ Supporting Trial Success?
As the effects of the pandemic reverberate through global supply chains, Sponsors still face many hurdles in sourcing and managing ancillary supplies for clinical trials. Interruptions and delays that once felt like temporary inconveniences are now long-term realities across the entire industry, and there is no choice except to adapt.
DCAT® Women Leaders in Pharma Interview Series: Dr. Joanne Santomauro
Dr. Joanne Santomauro, Chief Executive Officer and Founder of Ancillare, LP, created the Clinical Trial Ancillary Supply Chain (CTASC™) Management industry in 2006. Joanne’s 35 years of supply chain management expertise led the company to launch its market-leading model. Her leadership has resulted in Ancillare’s explosive growth throughout the world.
Ancillare’s Impact: Our Drive to Reach Further (And Closer)
Our work to make clinical trials run more smoothly helps our partners create hope for patients every day, all over the world.
Risk Management in Clinical Trials: How the CTASC™ Approach Strengthens Clinical Supply Chains
Minimizing interruptions in your Clinical Trial Ancillary Supply Chain lowers risk of delay in your trial timeline — potentially saving millions in overall trial costs.
Ensuring uninterrupted clinical supplies during a pandemic
Ancillare’s CEO, Dr. Joanne Santomauro, discusses how the organization overcame supply chain challenges in the height of the COVID-19 pandemic to source ancillary supplies for clinical trials.
Dry Eye Syndrome
Dry eye syndrome is a common condition with many ongoing studies around the globe. Read the overview by Ancillare’s Medical Director, including ancillary considerations for clinical supply chains.
Your Trials Deserve More Than an Ancillary Supply Vendor
This Clinical Trials Day, we are highlighting the individual areas of expertise that allows us to serve as much more than a supplier.
Armed Against ARMD – Insights for Providers, Patients, and Clinical Trial Sponsors
February is Age-Related Macular Degeneration (ARMD) and Low Vision Awareness month. Dr. Georgia Crozier, Medical Director and Subject Matter Expert at Ancillare, shares her decades of experience to raise public awareness on this common condition — and highlights the importance of a well-planned Clinical Trial Ancillary Supply Chain (CTASC™) in conducting research for potential treatments.
PharmaVOICE SHOWCASE: Supply Chain Management: The Supply Chain: Risks and Opportunities with Executive Viewpoints from Ancillare’s CEO
COVID-19 caused shockwaves throughout the global supply chain of every industry. For the pharmaceutical industry, the pandemic highlighted the fragility of the supply chain and the importance of being able to adjust to demand in a changed environment.
PharmaVOICE Technology Solutions: Disrupting Innovations with Digital Solutions with Executive Viewpoints from Ancillare’s CIO
Healthcare is undergoing a massive transformation with increased emphasis on digital technologies in all areas. According to Deloitte research, biopharma companies recognize that digital transformation will aid product and service innovation, greater customer engagement, and improvements across R&D, commercial, and the supply chain.
Tackling Ancillary Supply Challenges with Innovative Solutions
When a pharmaceutical client came to Joanne Santomauro nearly 15 years ago with a request to help with a complex and expensive ancillary supply challenge, she didn’t hesitate. She launched Ancillare and began the journey to create and revolutionize ancillary supply...
Clinical Trial Supply and Logistics Supplement: Quality assurance and regulatory compliance, and ancillary supply chain management
The clinical trial ancillary supply chain (CTASC) is extremely diverse and complex. Although the CTASC has evolved dramatically during most recent years, one element holds true – CTASC performance has the potential to significantly disrupt trial timelines and patient outcomes.
Clinical Trials Insights 2021 – Stay Ahead of the Supply Chain
A lack of correct ancillary supplies can be the difference between a clinical trial starting on time or having to delay at significant cost to the sponsor. The Covid-19 pandemic exacerbated what would already be a difficult task of sourcing and purchasing trial equipment. Ancillare CEO Joanne Santomauro explains how the situation developed and how her company stayed ahead of the curve and minimised the impact of shortages in the supply chain.
PharmaVOICE Supply Chain SHOWCASE: The Cost of Overlooking Ancillary Supplies in Protocol Development
What will it take to overcome grand-scale supply chain challenges, avoid massive business ramifications, and produce the best possible outcomes for patients worldwide?
DCAT® Women Leaders in Pharma Interview Series: Dr. Joanne Santomauro
Dr. Joanne Santomauro, Chief Executive Officer and Founder of Ancillare, LP, created the Clinical Trial Ancillary Supply Chain (CTASC™) Management industry in 2006. Joanne’s 35 years of supply chain management expertise led the company to launch its market-leading model. Her leadership has resulted in Ancillare’s explosive growth throughout the world.
Ensuring uninterrupted clinical supplies during a pandemic
Ancillare’s CEO, Dr. Joanne Santomauro, discusses how the organization overcame supply chain challenges in the height of the COVID-19 pandemic to source ancillary supplies for clinical trials.
PharmaVOICE SHOWCASE: Supply Chain Management: The Supply Chain: Risks and Opportunities with Executive Viewpoints from Ancillare’s CEO
COVID-19 caused shockwaves throughout the global supply chain of every industry. For the pharmaceutical industry, the pandemic highlighted the fragility of the supply chain and the importance of being able to adjust to demand in a changed environment.
PharmaVOICE Technology Solutions: Disrupting Innovations with Digital Solutions with Executive Viewpoints from Ancillare’s CIO
Healthcare is undergoing a massive transformation with increased emphasis on digital technologies in all areas. According to Deloitte research, biopharma companies recognize that digital transformation will aid product and service innovation, greater customer engagement, and improvements across R&D, commercial, and the supply chain.
Tackling Ancillary Supply Challenges with Innovative Solutions
When a pharmaceutical client came to Joanne Santomauro nearly 15 years ago with a request to help with a complex and expensive ancillary supply challenge, she didn’t hesitate. She launched Ancillare and began the journey to create and revolutionize ancillary supply...
The Future of Clinical Trials is Now
The COVID-19 pandemic has created numerous challenges for Sponsors worldwide, forcing clinical trials to adapt to changing conditions and innovate for the future simultaneously. Ancillare CEO Dr. Joanne Santomauro was interviewed on how proper supply plans are...